Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Century Therapeutics, Inc.IPSC · Entity 5739 | Chief Financial Officer | November 01, 2023 | November 03, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Century Therapeutics, Inc.
Report date November 01, 2023 · Filed November 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 253,533 |
Reported balance
After 2023-11-01 transaction · row 1
1 source rowRow 1 · 2023-11-01 · Tax withholding · Disposed 20,763 · Balance 253,533 F1: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 01, 2023 Filed Nov 3, 2023 20:04 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | Tax withholdingCommon Stock | 20,763 | $1.49 | $30,936.87 |
DisclosureSEC source: 0001062993-23-020089 · form4.xml · nonDerivative · entry 1 Diem Michael Craig · CIK 0001497624 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 253,533 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:32 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantCommon Stock | 151,058 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-011401 · form4.xml · nonDerivative · entry 1 Diem Michael Craig · CIK 0001497624 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 274,296 F1 · security: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Century Therapeutic, Inc.'s (the "Company's") common stock. The RSUs shall vest 50% on November 1, 2023, with the remaining 50% vesting upon the earlier of: (i) November 1, 2024; and (ii) satisfaction of certain performance criteria, in each case subject to the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Company's common stock. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 23:49 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantStock Option (right to buy) · Derivative | 131,250 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001062993-23-002307 · form4.xml · derivative · entry 4 Diem Michael Craig · CIK 0001497624 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,250 Underlying: Common Stock · 131,250 shares Expires 2033-02-02 F2 · derivative.exercise_date: The option vests 25% on February 2, 2024, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 23:49 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantStock Option (right to buy) · Derivative | 131,250 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001062993-23-002307 · form4.xml · derivative · entry 3 Diem Michael Craig · CIK 0001497624 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,250 Underlying: Common Stock · 131,250 shares Expires 2033-02-02 F2 · derivative.exercise_date: The option vests 25% on February 2, 2024, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 23:49 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantCommon Stock | 21,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-002307 · form4.xml · nonDerivative · entry 2 Diem Michael Craig · CIK 0001497624 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,238 F1 · security: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Century Therapeutic, Inc.'s (the "Company's") common stock. The RSUs vest 25% on February 2, 2024 and the remaining 75% vest on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Company's common stock. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 23:49 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantCommon Stock | 21,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-002307 · form4.xml · nonDerivative · entry 1 Diem Michael Craig · CIK 0001497624 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,363 F1 · security: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Century Therapeutic, Inc.'s (the "Company's") common stock. The RSUs vest 25% on February 2, 2024 and the remaining 75% vest on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Company's common stock. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 21:51 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantStock Option (right to buy) · Derivative | 105,000 | $0.00 Strike: $13.15 | $0.00 |
DisclosureSEC source: 0001062993-22-001691 · form4.xml · derivative · entry 1 Diem Michael Craig · CIK 0001497624 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2032-01-25 F1 · derivative.exercise_date: The option vests 25% on January 25, 2023, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.